NSCLC Stage II
12 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (NCT04865250) | University Hospital Heidelberg | 2021-01-07 |
| A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China (NCT04830826) | The First Affiliated Hospital of Guangzhou Medical University | 2020-07-09 |
| Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NCT04205552) | University Hospital, Essen | 2020-03-04 |
| Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer (NCT03999710) | Memorial Sloan Kettering Cancer Center | 2019-07-19 |
| The Role of Microbiota on the Development of Lung Cancer (NCT03454685) | Xiaorong Dong | 2018-01-30 |
| Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations (NCT01470716) | National Cancer Center, Korea | 2012-01-01 |
Track NSCLC Stage II automatically
Every clearance here is in the API, with alerts when new ones post.